Camponeschi, A. et al. Human CD38 regulates B cell antigen receptor dynamic organization in normal and malignant B cells. J. Exp. Med. 219, e20220201 (2022).
Article CAS PubMed PubMed Central Google Scholar
Mayer, K. A. et al. A randomized phase 2 trial of felzartamab in antibody-mediated rejection. N. Engl. J. Med. 391, 122–132 (2024).
Hogan, K. A., Chini, C. C. S. & Chini, E. N. The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Front. Immunol. 10, 1187 (2019).
Article CAS PubMed PubMed Central Google Scholar
Zeidler, J. D. et al. The CD38 glycohydrolase and the NAD sink: implications for pathological conditions. Am. J. Physiol. Cell Physiol. 322, C521–C545 (2022).
Article CAS PubMed PubMed Central Google Scholar
Boslett, J., Helal, M., Chini, E. & Zweier, J. L. Genetic deletion of CD38 confers post-ischemic myocardial protection through preserved pyridine nucleotides. J. Mol. Cell. Cardiol. 118, 81–94 (2018).
Article CAS PubMed PubMed Central Google Scholar
van de Donk, N. W. et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol. Rev. 270, 95–112 (2016).
Article PubMed PubMed Central Google Scholar
Langer, P. et al. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant. Cochrane Database Syst. Rev. 5, CD013595 (2024).
Loupy, A. & Lefaucheur, C. Antibody-mediated rejection of solid-organ allografts. N. Engl. J. Med. 379, 1150–1160 (2018).
Article CAS PubMed Google Scholar
Lamarthée, B. et al. Transcriptional and spatial profiling of the kidney allograft unravels a central role for FcyRIII+ innate immune cells in rejection. Nat. Commun. 14, 4359 (2023).
Article PubMed PubMed Central Google Scholar
Floege, J. et al. Felzartamab (anti-CD38) in patients with IgA nephropathy — interim results from the IGNAZ study. Nephrol. Dial. Transplant. 39 (Suppl. 1), 425 (2024).
留言 (0)